Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Nanomedicine: is the wave cresting?

Nature Reviews Drug Discovery volume 12, pages 171–172 (2013)Cite this article

Subjects

The field of nanomedicine has grown rapidly in recent years, but several issues are emerging that could constrain its future evolution, particularly if they are not appropriately acknowledged and the potential of nanomedicine is oversold.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Venditto, V. J. & Szoka, F. C. Jr. Cancer nanomedicines: So many papers so few drugs! Adv. Drug Deliv. Rev. 1 Oct 2012 (doi:10.1016/j.addr.2012.09.038).

    Article  CAS  PubMed  Google Scholar 

  2. Duncan, R. & Gaspar, R. Nanomedicine(s) under the microscope. Mol. Pharm. 8, 2101–2141 (2011).

    Article  CAS  PubMed  Google Scholar 

  3. Chauhan, V. et al. Delivery of molecular and nanoscale medicine to tumors: barriers and strategies. Annu. Rev. Chem. Biomol. Eng. 2, 281–298 (2011).

    Article  CAS  PubMed  Google Scholar 

  4. Cheng, Z. et al. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 338, 903–910 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Rugo, H. S. et al. CALGB 40502/NCCTG N063H: randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). J. Clin. Oncol. Abstr. S30, CRA1002 (2012).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rudy Juliano is the Boshamer Distinguished Professor at the University of North Carolina Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, USA. rudy_juliano@med.unc.edu,

    Rudy Juliano

Authors
  1. Rudy Juliano
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

Rudy Juliano holds NIH grants in the area of delivery of antisense and siRNA oligonucleotides.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Juliano, R. Nanomedicine: is the wave cresting?. Nat Rev Drug Discov 12, 171–172 (2013). https://doi.org/10.1038/nrd3958

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3958

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research